<DOC>
	<DOC>NCT02080091</DOC>
	<brief_summary>This observational study aims to assess the safety and effect of Iluvien® in DME patients considered insufficiently responsive to available therapies in a real life setting in Germany.</brief_summary>
	<brief_title>Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Adult patients of both sexes that have signed informed consent after detailed information about the characteristics of the observation by the physician DME based on physician's clinical evaluation and demonstrated on fundus photographs and/or optical coherence tomography (OCT); Vision impairment associated with DME Prior treatment with available therapies for DME; and Patients considered by the physician insufficiently responsive to available therapies Patients with contraindications according to the current Summary of Product Characteristics (SPC) The presence of preexisting glaucoma Active or suspected ocular or periocular infection The patient is hypersensitive to the active agent or to one of the excipients Elevated IOP Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>